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1  | INTRODUC TION
It is known that awake endotracheal intubation in newborns causes 
multiple harmful effects.1-3 Therefore, in 2001 consensus was 
reached that only in the delivery room and in life-threating situa-
tions associated with the unavailability of intravenous access, tra-
cheal intubation should be performed without the use of analgesia 
or sedation.4 Almost twenty years later, the most effective and 
safe premedication strategy in the newborn population is still to be 
determined. Propofol is considered one of the acceptable options5 
and is shown to be very easy in use.6 Therefore, propofol has been 
implemented into clinical practice.7-11
In the past decade, several studies have appeared reporting on 
the use of propofol for neonatal intubation, with somewhat con-
flicting results about the sedative effect related to dose.6,9,10,12,13 
Results regarding the hypotensive effect of propofol are probably 
even more conflicting, varying from no or only a slight decrease in 
blood pressure,6,11 to a more pronounced decrease in blood pressure 
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Abstract
Aim: To analyse the effects of different propofol starting doses as premedication for 
endotracheal intubation on blood pressure in neonates.
Methods: Neonates who received propofol starting doses of 1.0 mg/kg (n = 30), 
1.5 mg/kg (n = 23) or 2.0 mg/kg (n = 26) as part of a previously published dose-finding 
study were included in this analysis. Blood pressure in the 3 dosing groups was ana-
lysed in the first 60 minutes after start of propofol.
Results: Blood pressure declined after the start of propofol in all 3 dosing groups and 
was not restored 60 minutes after the start of propofol. The decline in blood pres-
sure was highest in the 2.0 mg/kg dosing group. Blood pressure decline was mainly 
dependent on the initial propofol starting dose rather than the cumulative propofol 
dose.
Conclusion: Propofol causes a dose-dependent profound and prolonged decrease 
in blood pressure. The use of propofol should be carefully considered. When using 
propofol, starting with a low dose and titrating according to sedative effect seems 
the safest strategy.
K E Y W O R D S
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and a high incidence of hypotension.9,10,13 Therefore, questions have 
been raised about the effectiveness and safety of propofol. In our 
recently performed propofol dose-finding trial (NEOPROP-2), we 
showed that propofol starting doses of 1.0 and 1.5 mg/kg were less 
effective in providing effective sedation compared to a propofol 
starting dose of 2.0 mg/kg. However, independent of the starting 
dose, propofol carried an unpredictable high risk of hypotension.14
The aim of the current study was to further analyse the effects 
of different propofol starting doses on blood pressure. With this in-
depth analysis of the effects of propofol on blood pressure, we aimed 
to provide guidelines for the use of propofol in clinical practice.
2  | METHODS
2.1 | Participants
Neonates from the previously published NEOPROP-2 trial were 
considered for inclusion.14 The NEOPROP-2 trial was a prospective 
multicentre dose-finding trial conducted at three level III Neonatal 
Intensive Care Units in the Netherlands. Neonates with a postna-
tal age of less than 28 days who needed nonemergency endotra-
cheal intubation were eligible for inclusion. Exclusion criteria were 
major congenital anomalies or neurologic disorders, upper air-
way anomalies, sedative or opioid administration in the preceding 
24 hours and previous inclusion in the trial. Haemodynamic insta-
bility and underlying illnesses that are accompanied with a greater 
risk of haemodynamic instability were no specific exclusion criteria. 
The haemodynamic status and risk of haemodynamic insufficiency 
were judged by the attending physician. If the attending physician 
judged the patient to be haemodynamically stable enough to receive 
propofol, the patient could be included in the trial. The study was 
registered at ClinicalTrials.gov (NCT02040909; EudraCT number 
2013-005572-17) and approved by the local medical ethics commit-
tee (NL47607.078.14, MEC-2014-0.68). For further details concern-
ing patient stratification, dose-finding approach and the assessment 
of effective sedation, we refer to the initial publication.14 In summary, 
dose-finding was performed by using a step-up-step-down approach, 
starting with a propofol dose of 1.0 mg/kg in 5 consecutive patients 
and adjusting the dose with steps of 0.5 mg/kg for the next 5 pa-
tients based on sedative effect and side effects of the previous dose. 
For this analysis, all patients from the NEOPROP-2 trial who received 
a propofol starting dose of 1.0, 1.5 and 2.0 mg/kg were included. 
Patients who received a different starting dose were excluded.
2.2 | Blood pressure assessment
Blood pressure was measured invasively if an indwelling arterial cathe-
ter was present. Data were collected every minute from 5 minutes be-
fore until 30 minutes after the start of propofol administration, every 
5 minutes from 30 to 60 minutes and every hour thereafter up to 
24 hours. When no arterial catheter was present, blood pressure was 
measured noninvasively by an appropriately sized cuff from 5 minutes 
before until 60 minutes after propofol administration and every hour 
thereafter until 24 hours. Propofol-induced hypotension was defined 
as a mean blood pressure (MBP) below postmenstrual age (PMA) de-
tected in the first hour after propofol administration. Treatment of hy-
potension was left to the discretion of the treating physician.
2.3 | Primary outcome measure
The primary outcome measure was the course of blood pressure 
over time in the first hour after start of propofol infusion relative 
to baseline blood pressure in three different initial propofol start-
ing doses (1.0, 1.5 and 2.0 mg/kg). Blood pressure measured within 
5 minutes before start of the propofol infusion was considered as 
baseline. Blood pressure data were obtained every 5 minutes from 
5 minutes to 60 minutes after the start of propofol infusion.
2.4 | Secondary outcome measures
Since the haemodynamic status of the patient could influence the pa-
tients' tolerability for propofol, we evaluated the incidence of hypoten-
sion and the change in MBP after start of propofol relative to the baseline 
MBP in relation to the haemodynamic status of the patient. For this pur-
pose, we included all patients in whom sufficient information regarding 
baseline MBP and MBP in the first hour after propofol was available, 
and divided these patients into three groups: group 1, haemodynami-
cally stable patients (no baseline hypotension and no sepsis/NEC); group 
2, patients with baseline hypotension; and group 3, patients with a high 
risk of haemodynamic failure because of sepsis or NEC as indication for 
intubation. To elucidate the influence of cumulative propofol doses on 
blood pressure, we also performed a secondary analysis into the maxi-
mum decrease in MBP after different cumulative propofol doses.
2.5 | Statistical analysis
Data analysis was performed using SPSS (IBM SPSS Statistics for 
Windows, version 22.0. Armonk, NY, USA) and Stata (Stata, version 
Key notes
• Propofol as premedication for neonatal endotracheal in-
tubation causes a profound and long-lasting decrease in 
blood pressure, which is mainly dependent on the start-
ing dose and not on the cumulative dose.
• Higher initial propofol starting doses cause a greater 
decrease in blood pressure compared to lower initial 
doses.
• Start low and titrate according to the sedative effect 
causes the least decrease in blood pressure and seems 
the safest strategy.
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15, StataCorp LLC, TX, USA). Baseline characteristics were de-
scribed by numbers and percentages for qualitative variables and 
median and interquartile range (IQR) for quantitative variables. 
Comparison between groups was performed with the Mann-
Whitney U test for continuous variables and the Fisher's exact 
test for categorical variables. Development of MBP over time-
epochs was expressed as absolute change compared to baseline. 
Comparison of MBP development between groups was determined 
using a linear mixed model analysis to take into account the de-
pendency of observations within patients. The linear mixed models 
included time (added to the model as a categorical variable repre-
sented by dummy variables), dose group and the interaction be-
tween time and dose group. Besides a crude analysis, also analyses 
adjusted for volume resuscitation and the administration of addi-
tional doses of propofol were performed. This was done by adding 
volume resuscitation and the administration of additional doses of 
propofol to the linear mixed models as time-dependent covariates. 
In addition, a linear mixed model analysis was performed with the 
cumulative dose of propofol as independent variable and the re-
peatedly measured MBP values as outcome.
3  | RESULTS
3.1 | Study population
Of the 91 patients in the NEOPROP-2 study, 79 patients received 
a starting dose of either 1.0, 1.5 or 2.0 mg/kg of propofol and were 
included in this analysis. Median gestational age was 27.71 weeks (IQR 
25.86-30.71), median birthweight was 1065 g (IQR 860-1560), and 
the median postnatal age at intubation was 33.53 hours (IQR 8.37-
279.53). Fifty-two patients (66%) were boys, and 18 patients (23%) 
had a birthweight below the 10th percentile. Thirty patients (38%) 
received a propofol starting dose of 1.0 mg/kg, 23 patients (29%) re-
ceived a propofol starting dose of 1.5 mg/kg, and 26 patients (33%) 
received a propofol starting dose of 2.0 mg/kg. Patient characteristics, 
sedative effect of propofol and need for extra propofol doses in these 
3 dosing groups are presented in detail in the initial publication.14 A 
summary of these findings relevant to the purpose of this analysis is 
presented in Table 1.
3.2 | Primary outcome measure
3.2.1 | Occurrence of hypotension and lowest MBP 
in 3 dosing groups
In Table 2, data on MPB before administration of propofol, the defi-
nition of hypotension and data on MBP after start of propofol in 
the 3 dosing groups are presented. These data show that the inci-
dence of hypotension was not significantly different between the 
3 groups. In the 2.0 mg/kg group, more patients were treated with 
volume resuscitation (75%) compared to the 1.0 mg/kg (47%) and 
1.5 mg/kg (36%) groups, but this difference did not reach statisti-
cal significance. The maximum decrease in MBP as percentage from 
baseline was equal in all 3 groups. However, this maximum decrease 
TA B L E  1   Patient characteristics and sedative effect in 3 different propofol starting doses (see original report14 for details)
 






(n = 26) 1.0 vs 1.5 1.0 vs 2.0 1.5 vs 2.0
Gestational age (wk), median 
(IQR)
27.5 (25.86-30.93) 26.86 (25.57-30.14) 29.07 (26.43-31.71) P = .37 P = .66 P = .20
Birthweight (g), median (IQR) 1075 (784-1410) 908 (780-1600) 1215 (895-1568) P = .46 P = .51 P = .19
Postnatal age (h), median (IQR) 125 (12-397) 37.35 (21-387) 19.58 (8-43) P = .68 P = .01 P = .04
Male gender, n (%) 22 (73) 12 (52) 18 (69) P = .16 P = .77 P = .25
Reason for intubation, n (%)    P = .53 P = .27 P = .35
RDS 12 (40) 8 (34.8) 17 (65.4)    
Apnoea 6 (20) 8 (34.8) 4 (15.4)    
Sepsis/NEC 4 (13.3) 3 (13) 2 (7.7)    
Respiratory insufficiency 7 (23.3) 2 (8.7) 2 (7.7)    
Elective 1 (3.3) 1 (4.3) 0    
Other 0 1 (4.3) 1 (3.8)    
Effective sedation, n (%) 1/28 (4) 3/23 (13) 18/24 (86) P = .21 P < .001 P < .001
Extra propofol administered, 
n (%)
25 (83) 20 (87) 11 (42) P = 1.0 P = .002 P = .002
Cumulative propofol dose (mg/
kg), median (IQR)
3.0 (1.9-4.0) 3.4 (2.5-4.5) 2.0 (2.0-3.0) P = .06 P = .97 P = .03
Abbreviations: IQR, interquartile range; NEC, necrotising enterocolitis; RDS, respiratory distress syndrome.
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was reached significantly earlier in the 1.0 mg/kg group (18.2 min-
utes) compared to the 2.0 mg/kg group (28.6 minutes; P = .04).
3.2.2 | Absolute changes in MBP after propofol 
in the 3 dosing groups
The absolute changes in blood pressure compared to baseline at dif-
ferent time intervals after the start of propofol infusion for the 3 
dosing groups are presented in Figure 1. These data show that MBP 
declined in all 3 groups compared to baseline and that this decline 
was highest in the 2.0 mg/kg dosing group. In the 1.0 mg/kg group, 
the decline in MBP from baseline was significant at 20, 25, 35 and 
45 minutes after start of propofol administration. In the 1.5 mg/kg 
group, the decline from baseline was significant at time points 5 up 
to and including 30 minutes and 55 minutes after start of propofol. 
Finally, in the 2.0 mg/kg group the decline in MBP from baseline was 
significant at all time points with the exception of 5 minutes after the 
start of propofol. Correcting for volume resuscitation and the admin-
istration of extra doses of propofol did not alter the results from the 
initial analysis (Figure 2).
3.3 | Secondary outcome measures
3.3.1 | Changes in MBP in relation to 
haemodynamic status
For this analysis, we included 69 patients of whom sufficient data 
regarding baseline MBP and MBP in the first hour after propofol 
were available. The results of the analysis are presented in Table 3. 
The incidence of hypotension was, as expected, significantly higher 
in group 2, and the lowest MBP after start of propofol was signifi-
cantly lower in this group. The incidence of hypotension, the lowest 
MBP after start of propofol and the maximum decrease in MBP after 
propofol were equal between group 1 and group 3.
3.3.2 | Changes in MBP in relation to cumulative 
propofol dose
Independent of the propofol starting doses that were administered, 
we also analysed the average change in MBP over time for different 
cumulative doses of propofol, independent of the propofol start-
ing dose. The results of this analysis are shown in Table 4. In all 
cumulative doses, MBP significantly declined compared to baseline, 
with the largest declines in the 1.0 and 2.5 mg/kg cumulative doses. 
These results have to be interpreted with some caution because 
of the small patient numbers, but could indicate that the cumula-
tive dose of propofol did not influence the decline in MBP after 
propofol.
4  | DISCUSSION
This post hoc analysis was performed to explore the effects of dif-
ferent propofol starting doses as premedication for endotracheal 
intubation on blood pressure. The results of this analysis show that 
propofol starting doses of 1.0 mg/kg, 1.5 mg/kg and 2.0 mg/kg all 
caused a profound and prolonged decline in blood pressure. In all 
three dosing groups, MBP decreased by a maximum of 30%-35% in 
comparison with the baseline MBP, and MBP was not restored after 
one hour. The decrease in blood pressure was most pronounced with 
a propofol starting dose of 2.0 mg/kg. The incidence of hypotension 
was over 50% in all groups. The blood pressure decline was mainly 
dependent on the starting dose that was used and less influenced 
by the cumulative propofol dose that was administered to achieve 
successful endotracheal intubation.
TA B L E  2   Blood pressure data in 3 different dosing groups
 






(n = 26) 1.0 vs 1.5 1.0 vs 2.0 1.5 vs 2.0
Baseline MBP (mm Hg), mean (SD) 40.5 (11.2) 44.4 (9.7) 42.4 (12.3) P = .22 P = .73 P = .30
Hypotension before propofol, n (%) 4/29 (14) 0/21 3/26 (12) P = .13 P = 1.0 P = .24
Hypotension at any time point after start of propofol, 
n (%)
15/24 (63) 11/21 (52) 16/26 (62) P = .56 P = 1.0 P = .57
Treatment of hypotension with volume resuscitation, 
n (%)
7/15 (47) 4/11 (36) 12/16 (75) P = .70 P = .15 P = .06
Lowest MBP (mm Hg) after start of propofol, mean 
(SD)
27.8 (9.5) 27.8 (6.9) 27.1 (5.5) P = .85 P = .73 P = .88
Time after start of propofol (min) of lowest MBP, 
mean (SD)
18.2 (12.5) 22.6 (14.3) 28.6 (18.2) P = .24 P = .04 P = .25
Maximum decrease in MBP as % from baseline, mean 
(SD)
−30 (16.5) −36.4 (14.0) −32.6 (18.7) P = .07 P = .15 P = .73
Abbreviations: MBP, mean blood pressure; SD, standard deviation.
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To the best of our knowledge, this is the first study to evaluate 
the effect of different propofol doses on blood pressure. Comparison 
with data from the literature, therefore, is somewhat difficult. In 
our analysis, propofol-induced hypotension was observed in 63%, 
52% and 62% of the patients receiving a propofol starting dose of 
1.0 mg/kg, 1.5 mg/kg and 2.0 mg/kg, respectively. Previous liter-
ature shows somewhat controversial effects of propofol on blood 
pressure in newborns. Smits et al,13 in their dose-finding study, 
found an incidence of hypotension of 64% in the entire population 
irrespective of the starting dose that was administered. Welzing 
et al and Simons et al both reported an incidence of propofol-in-
duced hypotension of 39%.9,10 In their randomised controlled trial 
comparing propofol to sufentanil and atracurium, Durrmeyer et al12 
found hypotension to occur in 13.3% of the patients in the propofol 
group. In contrast to these findings, others reported no hypotension 
to occur in their study population treated with propofol for endotra-
cheal intubation.6,11
Part of these controversial results might be found in different 
definitions used for hypotension in preterm infants. Even in the 21st 
century, there is no generally accepted definition. Without any evi-
dence to support it, the most popular criterion to define hypotension 
is MBP below gestational age.15,16 The second most used definition 
is a MBP below the 10th or 5th percentile.16 There are numerous 
reference ranges, often based on gestational age, birthweight and 
postnatal age criteria, with considerable variation among these ref-
erence ranges.15,17 Finally, MBP below 30 mm Hg is used to define 
hypotension, because some studies found loss of cerebral autoregu-
lation below this threshold.16,18,19
In our study and in the study of Smits et al,13,14 the MBP below 
gestational age criterion was used. Both studies also used this 
F I G U R E  1   Changes of systolic, diastolic and mean blood pressure after start of propofol in 3 dosing groups
F I G U R E  2   Changes in MBP after correcting for volume resuscitation and extra propofol administration
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definition for infants beyond the first 72 hours of life and therefore 
somewhat modified the definition to MPB below postmenstrual 
age. Simons et al9 also used the MBP below gestational age crite-
rion but only reported on hypotension of a severity that required 
treatment. This could explain why they found a lower incidence of 
hypotension of 39%. Should we have only reported on hypotension 
that required treatment, our incidence of hypotension should have 
been 32%. Welzing et al10 used a much more liberal definition of 
MBP less than 25 mm Hg in a study population with a gestational age 
of 29-32 weeks. Should they have used the MBP below gestational 
age criterion, the incidence of hypotension would have been much 
higher.
Hypotension in the preterm infant has been associated with 
mortality, cerebral injury such as intraventricular haemorrhage 
and periventricular leukomalacia, and long-term neurologic se-
quelae.16,20-24 The question arises, however, if every infant with 
low blood pressure needs treatment for hypotension. Blood pres-
sure is only one aspect of cardiovascular status and may not directly 
correlate with tissue perfusion. Infants with hypotension in the 
absence of biochemical or clinical signs of shock presumably have 
adequate tissue oxygen delivery, a phenomenon indicated as per-
missive hypotension.15 It has been shown that infants with permis-







N = 9 P-value
Propofol starting dose, n (%)    .35
1.0 mg/kg 16 (30.2) 4 (57.1) 4 (44.4)  
1.5 mg/kg 16 (30.2) 0 3 (33.3)  
2.0 mg/kg 21 (39.6) 3 (42.9) 2 (22.2)  
Baseline MBP (mm Hg), 
mean (SD)
44.5 (10.2) 25.3 (3.1) 42.7 (10.5) <.001
Absolute difference 
between baseline MBP 
and MBP indicating 
hypotension (mm Hg), 
mean (SD)
15.0 (9.8) −4.1 (4.0) 14.9 (9.8) <.001
Relative difference between 
baseline MBP and MBP 
indicating hypotension (%), 
mean (SD)
54 (35.9) −13.6 (12.4) 53 (34.2) <.001
Hypotension at any time 
point after propofol 
administration, n (%)
28 (52.8) 7 (100) 6 (66.7) .05
Treatment of hypotension 
with volume resuscitation, 
n (%)
10/28 (36) 3/7 (43) 2/6 (33) .28
Lowest MBP (mm Hg) after 
start of propofol, mean 
(SD)
28.5 (7.2) 20.9 (4.3) 27 (7.8) .01
Time after start of propofol 
(min) of lowest MBP, mean 
(SD)
23.5 (16.2) 19.9 (12.5) 24.8 (17.7) .88
Maximum decrease in MBP 
as % from baseline, mean 
(SD)
−34.3 (16.6) −16.9 (16.1) −35.9 (11.7) .05
Note: Group 1 = haemodynamically stable (no baseline hypotension and no sepsis/NEC; group 
2 = baseline hypotension; group 3 = high risk of haemodynamic failure based on sepsis or NEC as 
underlying morbidity.
Abbreviations: MBP, mean blood pressure; NEC, necrotising enterocolitis; SD, standard deviation.
TA B L E  3   Analysis of blood pressure in 
relation to haemodynamic stability
TA B L E  4   MBP changes in different cumulative propofol doses
Cumulative 
propofol dose





1 mg/kg −8.9 −12.8 −5.0 <.001
1.5 mg/kg −4.8 −8.8 −0.9 .02
2 mg/kg −2.8 −5.2 −0.4 .02
2.5 mg/kg −9.4 −14.7 −4.2 <.001
3 mg/kg −4.9 −7.6 −2.3 <.001
≥3.5 mg/kg −4.3 −6.7 −1.8 .001
Abbreviations: MBP, mean blood pressure.
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similar outcomes as normotensive patients.25 A recent French pop-
ulation-based cohort study, however, showed that preterm infants 
below 29 weeks' gestation who were treated for hypotension in the 
first 72 hours of life had significantly higher survival rates without 
major morbidity and a lower rate of severe cerebral abnormalities, 
compared to infants with hypotension who were untreated.26 These 
conflicting results indicate that the importance of hypotension in the 
preterm population is still to be elucidated.
Despite the statement that the haemodynamic status of the pa-
tients needed to be sufficiently stable to administer propofol, seven 
patients were hypotensive before the start of propofol. Besides this, 
nine patients received propofol while being at risk for haemodynamic 
insufficiency based on sepsis or NEC as underlying illness. Inclusion of 
these (possible) haemodynamically instable patients could have influ-
enced the results and could have magnified the effect of propofol on 
blood pressure. Our analysis on the influence of haemodynamic sta-
tus on the effect of propofol in blood pressure, however, shows that 
the effect of propofol on blood pressure is not different between pa-
tients who are presumed to be haemodynamically stable and infants 
who are presumed to have an increased risk of haemodynamic failure 
based on sepsis or NEC. Although caution with the interpretation 
of these results is warranted because of the small patient numbers, 
these data suggest that the tolerance for propofol in haemodynami-
cally stable patients is not different from haemodynamically compro-
mised patients. It should also be kept in mind that these results could 
also indicate that the haemodynamically stable patients in group 1 
were not as haemodynamically stable as they were presumed to be.
In our initial analysis, we showed that a propofol starting dose 
of 2.0 mg/kg provided effective sedation in 86% of patients, com-
pared to 4% and 13% of the patients who received a starting dose of 
1.0 mg/kg or 1.5 mg/kg, respectively.14 Solely based on the sedative 
effect of propofol, a starting dose of 2.0 mg/kg of propofol would 
be the best strategy. However, despite an equal incidence of hypo-
tension compared to the 1.0 mg/kg starting dose, a dose of 2.0 mg/
kg had a much more profound decrease in blood pressure despite a 
lower cumulative propofol dose compared to the 1.0 mg/kg group. 
Therefore, when using propofol as premedication for endotracheal 
intubation, the safest strategy seems to start with a low dose of 
1.0 mg/kg and titrating until effective sedation has been reached.
The above-mentioned advice answers the question which 
propofol strategy for endotracheal intubation in preterm neonates 
is the safest. The question if this is safe enough and if it is justi-
fied to continue using propofol as premedication for endotracheal 
intubation in newborns still needs to be answered. The statement 
on hypotension without clinical and biochemical signs of poor per-
fusion being permissive concerns the spontaneous course of blood 
pressure of extremely preterm infants in the first 72 hours of life.17 
Although most of the patients in our analysis were within their first 
72 hours of life, the occurrence of hypotension was not spontaneous 
but induced by the administration of propofol. Although one-third of 
patients in each of our 3 study groups did not fulfil our criteria of hy-
potension, MBP significantly decreased relative to baseline in almost 
all patients and this decrease was not restored 60 minutes after the 
start of propofol administration. Thewissen et al27 showed that ce-
rebral autoregulation stayed intact during episodes of hypotension 
caused by propofol. Two other reports also could not demonstrate 
an important correlation between blood pressure and cerebral ox-
ygenation in the neonatal population.28,29 Although these data are 
somewhat reassuring, the possible negative effects on short- and 
long-term outcomes of hypotension induced by the use of propofol 
are not known and possibly by far not as permissive as we might 
think. Neonatologists should ask themselves if they would expose 
the most vulnerable (extremely preterm) neonates to this side effect 
with unknown consequences on the short and on the long term. In 
our opinion, the effect of propofol on blood pressure is a safety con-
cern and the use of propofol should be carefully considered in every 
individual patient. Studies into the short-term and long-term effects 
of propofol-induced hypotension and comparison to alternative pre-
medication strategies are warranted if propofol is continued to be 
used for this purpose in this population.
There are some limitations to our study. At first, not all patients 
in our study population had indwelling arterial catheters, and there-
fore, invasively and noninvasively measured blood pressure data 
were combined. Secondly, data of near-infrared spectroscopy mon-
itoring were missing on a large scale, and consequently, we have no 
data on cerebral oxygenation during propofol treatment.
5  | CONCLUSION
Propofol used as premedication to sedate neonates for endotracheal 
intubation causes a profound and prolonged decrease in MBP which 
is more pronounced with a higher starting dose. It also causes a 
high incidence of propofol-induced hypotension, irrespective of the 
starting dose that is used. Although premedication for endotracheal 
intubation is essential, propofol might not be the preferred drug. 
When propofol is used in neonates, starting with a low dose and 
titrating according to sedative effect seems the safest strategy with 
the least pronounced effect on blood pressure.
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